Centrum 7/6  banner

budesonide inhalation suspension

Lupin releases budesonide inhalation suspension

Lupin releases budesonide inhalation suspension

BALTIMORE — Lupin announced the launch of its budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules in the U.S. market, having received an approval from the United States Food and Drug Administration earlier. Lupin’s budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules is a generic version of AstraZeneca Pharmaceuticals LP’s Pulmicort Respules Inhalation Suspension, 0.5

Lupin gets FDA approval for budesonide inhalation suspension

Lupin gets FDA approval for budesonide inhalation suspension

MUMBAI, India and BALTIMORE, Md. — Pharma major Lupin announced that it has received approval for its budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules from the United States Food and Drug Administration to market a generic version of AstraZeneca Pharmaceuticals LP’s (AstraZeneca) Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL. Lupin’s budesonide inhalation suspension, 0.5

Sandoz releases Pulmicort Respules generic

PRINCETON, N.J. — Sandoz has launched budesonide inhalation suspension, an asthma medication, in the U.S. market. The Novartis subsidiary said Tuesday that it will market its budesonide inhalation suspension in 1-mg strength, and it expects 180-day generic drug marketing exclusivity for that dosage. The product is a a generic version of Pulmicort Respules inhalation suspension

PP_1170x120_10-25-21